Heron Therapeutics (HRTX) Receives CRL for HTX-011 for Management of Postoperative Pain
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Heron Therapeutics (HRTX) PT Lowered to $34 at Cowen; Launch Likely Pushed to Mid-2021
June 29, 2020 10:56 AM EDTCowen analyst Boris Peaker lowered the price target on Heron Therapeutics (NASDAQ: HRTX) to $34.00 (from $39.00) while maintaining an Outperform rating.
The analyst commented, "Heron received a CRL for HTX-011 requesting additional nonclinical information. The CRL is related to excipient exposure levels from... More
Heron Therapeutics (HRTX) said defended at Evercore ISI
June 29, 2020 10:14 AM EDTHeron Therapeutics (NASDAQ: HRTX) said defended at Evercore ISI, saying they are buyers on weakness.
... MoreHeron Therapeutics (HRTX) to Resume Trading at 9:10 a.m.
June 29, 2020 8:48 AM EDTHeron Therapeutics (NASDAQ: HRTX) to Resume Trading at 9:10 a.m.
Heron Therapeutics (HRTX) Halted, News Pending
June 29, 2020 8:40 AM EDTHeron Therapeutics (NASDAQ: HRTX) Halted, News Pending
